Gemzar Ovarian Cancer Negative Review Shows Discomfort With Ex-U.S. Data

The Oncologic Drugs Advisory Committee's negative review of Lilly's Gemzar for treatment of ovarian cancer illustrates the difficulty of receiving approval for submissions based on solely ex-U.S. trials lacking FDA input on design